The FDA has announced it will vote this week on whether a class of drugs that treat opioid-induced constipation needs more clinical testing in light of a side effect: heart attack. The class of drugs includes recently approved products from Salix Pharmaceuticals and Cubist Pharmaceuticals but also one that AstraZeneca is developing with Nektar Theraputics.
Lawsuits have been piling up against Abbott Laboratories and its recent spinoff, AbbVie, maker of one of the top-selling testosterone supplements, AndroGel. A panel of judges has now decided that those suits will be consolidated in Chicago, where both companies are based.
While Victoza brought in more than $2 billion last year, it has been dogged by concerns that it raises the risk of pancreatitis--and despite it and other similar drugs being cleared by reviews by both the FDA and EU regulators this year, some keep pushing the FDA to consider pulling it off the market.
Europe has been pushing the U.S. in trade negotiations to accept their inspections of European drugmakers in lieu of doing their own, and vice versa, but the approach the FDA and European regulators have taken to problems at a Ranbaxy Laboratories plant illustrate why this has become a contentious issue.
Regulators in Vietnam have banned drug imports from dozens of companies, saying they are substandard.
FDA's May 28 approval of Natesto, the first nasally delivered testosterone gel for hypogonadism, came just in time for Canada's Trimel Pharmaceuticals, which had just $18 million left on hand at the beginning of the year.
In the wake of a lawsuit brought by two California counties against five manufacturers of prescription painkillers, the city of Chicago has filed a suit of its own. Chicago is suing the same five pharma companies--alleging, much like California does, that they overstated the benefits of opioid painkillers while deceiving the public about the risks.
Just after Pfizer made a massive drug recall in March, Indian manufacturer Zydus Cadila is now scrambling to pull 10,200 bottles of allergy pills from shelves manufactured by its U.S. unit after the discovery of a blood pressure pill.
Novartis has to face a kickbacks lawsuit filed by the U.S. Department of Justice, which alleges that the Swiss drugmaker gave pharmacies discounts and rebates to boost sales of two drugs, a federal judge ruled Thursday.
The FDA said today Zydus Cadila has recalled 10,200 bottles of its allergy drug promethazine hydrochloride after a high blood pressure medication was discovered in one of its bottles.